CA2811493C - Method for separating target molecules or particles from fibrinogen-containing samples including blood components - Google Patents
Method for separating target molecules or particles from fibrinogen-containing samples including blood components Download PDFInfo
- Publication number
- CA2811493C CA2811493C CA2811493A CA2811493A CA2811493C CA 2811493 C CA2811493 C CA 2811493C CA 2811493 A CA2811493 A CA 2811493A CA 2811493 A CA2811493 A CA 2811493A CA 2811493 C CA2811493 C CA 2811493C
- Authority
- CA
- Canada
- Prior art keywords
- fibrinogen
- sample
- fibrin
- particles
- thrombin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010049003 Fibrinogen Proteins 0.000 title claims abstract description 175
- 102000008946 Fibrinogen Human genes 0.000 title claims abstract description 175
- 229940012952 fibrinogen Drugs 0.000 title claims abstract description 159
- 239000002245 particle Substances 0.000 title claims abstract description 97
- 238000000034 method Methods 0.000 title claims abstract description 90
- 239000012503 blood component Substances 0.000 title description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 155
- 102000009123 Fibrin Human genes 0.000 claims abstract description 152
- 108010073385 Fibrin Proteins 0.000 claims abstract description 152
- 229950003499 fibrin Drugs 0.000 claims abstract description 152
- 239000000523 sample Substances 0.000 claims description 221
- 210000004369 blood Anatomy 0.000 claims description 107
- 239000008280 blood Substances 0.000 claims description 107
- 108090000190 Thrombin Proteins 0.000 claims description 61
- 229960004072 thrombin Drugs 0.000 claims description 57
- 238000009739 binding Methods 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 19
- 239000003114 blood coagulation factor Substances 0.000 claims description 19
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 18
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 239000000654 additive Substances 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000006249 magnetic particle Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 claims description 11
- 230000009089 cytolysis Effects 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 229940012444 factor xiii Drugs 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 8
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 7
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 239000002738 chelating agent Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 108010071289 Factor XIII Proteins 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 6
- 102000025748 fibrinogen binding proteins Human genes 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 108091009104 fibrinogen binding proteins Proteins 0.000 claims description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims 4
- 206010057248 Cell death Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 238000000926 separation method Methods 0.000 description 29
- 238000001514 detection method Methods 0.000 description 28
- 244000005700 microbiome Species 0.000 description 22
- 241000191967 Staphylococcus aureus Species 0.000 description 21
- 239000008188 pellet Substances 0.000 description 21
- 210000001772 blood platelet Anatomy 0.000 description 20
- 239000012141 concentrate Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 206010040047 Sepsis Diseases 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960005069 calcium Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000002345 thrombinlike Effects 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000009640 blood culture Methods 0.000 description 4
- 239000003633 blood substitute Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108091005573 modified proteins Proteins 0.000 description 4
- 102000035118 modified proteins Human genes 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000005464 sample preparation method Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003914 blood derivative Substances 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- -1 specific antibodies Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 101710198480 Clumping factor A Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000000157 blood function Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002004 Afibrinogenemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000289427 Didelphidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 101900214495 Staphylococcus aureus Fibrinogen-binding protein Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01478/10 | 2010-09-15 | ||
| CH14782010 | 2010-09-15 | ||
| CH20412010 | 2010-12-07 | ||
| CH02041/10 | 2010-12-07 | ||
| CH01207/11 | 2011-07-20 | ||
| CH12072011 | 2011-07-20 | ||
| PCT/IB2011/054035 WO2012035508A2 (en) | 2010-09-15 | 2011-09-15 | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2811493A1 CA2811493A1 (en) | 2012-03-22 |
| CA2811493C true CA2811493C (en) | 2020-06-16 |
Family
ID=45044632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2811493A Active CA2811493C (en) | 2010-09-15 | 2011-09-15 | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9689881B2 (enExample) |
| EP (2) | EP2616550B1 (enExample) |
| JP (1) | JP5999776B2 (enExample) |
| KR (1) | KR101948944B1 (enExample) |
| CN (2) | CN107389932B (enExample) |
| AU (2) | AU2011303467C1 (enExample) |
| CA (1) | CA2811493C (enExample) |
| CY (1) | CY1122166T1 (enExample) |
| DK (2) | DK2616550T3 (enExample) |
| ES (2) | ES2751660T3 (enExample) |
| HR (1) | HRP20191785T1 (enExample) |
| HU (2) | HUE028915T2 (enExample) |
| LT (1) | LT3067431T (enExample) |
| PL (2) | PL2616550T3 (enExample) |
| PT (1) | PT3067431T (enExample) |
| SI (1) | SI3067431T1 (enExample) |
| WO (1) | WO2012035508A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12398176B2 (en) | 2018-08-27 | 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Use of Raman spectroscopy in downstream purification |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9689881B2 (en) | 2010-09-15 | 2017-06-27 | Spinomix S.A. | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
| CN103702674B (zh) | 2011-06-27 | 2018-05-29 | 爱默蕾大学 | 血小板裂解物的组合物、用途和制备 |
| EP2979093B1 (en) * | 2013-03-29 | 2019-10-23 | Siemens Healthcare Diagnostics Inc. | Rare cell concentration |
| ES2740838T3 (es) * | 2014-06-01 | 2020-02-06 | Debiopharm Int Sa | Dispositivo de recolección y procesamiento de muestras |
| US12397302B2 (en) | 2015-11-30 | 2025-08-26 | Dh Technologies Development Pte. Ltd. | Electromagnetic assemblies for processing fluids |
| WO2017156375A1 (en) | 2016-03-10 | 2017-09-14 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
| WO2017156379A2 (en) | 2016-03-10 | 2017-09-14 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
| JP7298449B2 (ja) * | 2019-11-14 | 2023-06-27 | 株式会社島津製作所 | 血液凝固分析装置、及び分注ノズルの洗浄方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1035260A (en) * | 1974-08-12 | 1978-07-25 | Baxter Travenol Laboratories | Collection and processing tube |
| FR2625321B1 (fr) * | 1987-12-24 | 1992-10-02 | Pasteur Institut | Reactif pour le diagnostic de staphylococcus aureus par agglutination |
| DE58902472D1 (de) * | 1988-01-05 | 1992-11-26 | Linhart Axel | Verfahren und test-kit zur semiquantitativen bestimmung des kalziumgehaltes im blut. |
| DE3803463A1 (de) * | 1988-02-05 | 1989-08-17 | Linhart Axel | Semiquantitativer kalzium-schnelltest |
| US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
| EP0587398B1 (en) * | 1992-09-09 | 1998-01-14 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
| JP3292760B2 (ja) * | 1993-04-22 | 2002-06-17 | テルモ株式会社 | 採血管およびその製造方法 |
| US5670329A (en) * | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| WO1995015397A1 (en) | 1993-12-03 | 1995-06-08 | Dorn Gordon L | Method for improving quantitative recovery of microorganisms fro m specimens containing blood components |
| DE19602673A1 (de) * | 1996-01-25 | 1997-08-07 | Pereg Gmbh | Synthetische Testanschmutzung |
| US6121232A (en) * | 1997-01-31 | 2000-09-19 | Omrix Biopharmaceuticals Sa | Stabilized mixture comprising fibrinogen |
| US6680195B1 (en) * | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| JP2000262499A (ja) * | 2000-01-01 | 2000-09-26 | Terumo Corp | 採血管 |
| US6686204B2 (en) * | 2001-08-27 | 2004-02-03 | Becton, Dickinson & Company | Collection device |
| WO2003028743A1 (en) * | 2001-10-03 | 2003-04-10 | Woolverton Christopher J | Storage-stable fibrinogen solutions |
| JP4718833B2 (ja) * | 2002-05-01 | 2011-07-06 | シナプス ベスローテン フェンノートシャップ | 複合生物媒体における、一時的なタンパク質分解活性の濃度を決定するための診断試験 |
| EP1400589B1 (de) | 2002-09-18 | 2006-08-09 | SIRS-Lab GmbH | Verfahren zum Nachweis prokaryontischer DNA |
| SI1654387T1 (sl) * | 2003-08-15 | 2009-10-31 | Univ South Florida | Materiali in postopki za ujetje patogenov in odstranitev avrintrikarboksilne kisline iz vzorca |
| US20050065454A1 (en) * | 2003-09-22 | 2005-03-24 | Becton, Dickinson And Company | Non-evacuated blood collection tube |
| US7399609B2 (en) * | 2003-12-30 | 2008-07-15 | 3M Innovative Properties Company | Staphylococcus detection |
| US8419722B2 (en) * | 2004-10-29 | 2013-04-16 | Spinal Restoration, Inc. | Apparatus and method for injection of fibrin sealant in spinal applications |
| DE102005009479A1 (de) | 2005-03-02 | 2006-09-07 | Molzym Gmbh & Co. Kg | Verwendung von Nukleasen zum Abbau von Nukleinsäure in Gegenwart von chaotropen Agenzien und/oder Tensiden |
| US20100009409A1 (en) * | 2005-07-29 | 2010-01-14 | Ecole Polytechnique Federale De Lausanne | Molecular variant fibrinogen fusion proteins |
| US20080299587A1 (en) * | 2007-05-03 | 2008-12-04 | Dennis Durbin | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| CA2693565C (en) | 2007-08-02 | 2015-05-26 | Universite Laval | Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids |
| JP5029217B2 (ja) * | 2007-08-27 | 2012-09-19 | 東レ株式会社 | シート状物の製造方法 |
| ES2585246T3 (es) * | 2008-07-09 | 2016-10-04 | Profibrix Bv | Fibrinógeno recombinante |
| CA2768485C (en) | 2009-07-16 | 2018-12-04 | Timothy Foster | Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a |
| US9689881B2 (en) | 2010-09-15 | 2017-06-27 | Spinomix S.A. | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
-
2011
- 2011-09-15 US US13/822,209 patent/US9689881B2/en active Active
- 2011-09-15 CA CA2811493A patent/CA2811493C/en active Active
- 2011-09-15 EP EP11788227.4A patent/EP2616550B1/en active Active
- 2011-09-15 AU AU2011303467A patent/AU2011303467C1/en active Active
- 2011-09-15 DK DK11788227.4T patent/DK2616550T3/en active
- 2011-09-15 CN CN201710338814.XA patent/CN107389932B/zh active Active
- 2011-09-15 JP JP2013528815A patent/JP5999776B2/ja active Active
- 2011-09-15 KR KR1020137009329A patent/KR101948944B1/ko active Active
- 2011-09-15 LT LT16154770T patent/LT3067431T/lt unknown
- 2011-09-15 DK DK16154770.8T patent/DK3067431T3/da active
- 2011-09-15 HU HUE11788227A patent/HUE028915T2/en unknown
- 2011-09-15 CN CN201180044211.XA patent/CN103108959B/zh active Active
- 2011-09-15 ES ES16154770T patent/ES2751660T3/es active Active
- 2011-09-15 PL PL11788227T patent/PL2616550T3/pl unknown
- 2011-09-15 PL PL16154770T patent/PL3067431T3/pl unknown
- 2011-09-15 SI SI201131797T patent/SI3067431T1/sl unknown
- 2011-09-15 EP EP16154770.8A patent/EP3067431B1/en active Active
- 2011-09-15 ES ES11788227T patent/ES2571127T3/es active Active
- 2011-09-15 HU HUE16154770A patent/HUE045771T2/hu unknown
- 2011-09-15 PT PT161547708T patent/PT3067431T/pt unknown
- 2011-09-15 WO PCT/IB2011/054035 patent/WO2012035508A2/en not_active Ceased
-
2016
- 2016-12-02 AU AU2016266066A patent/AU2016266066B2/en active Active
-
2017
- 2017-05-22 US US15/601,677 patent/US20170336424A1/en not_active Abandoned
-
2019
- 2019-10-02 HR HRP20191785TT patent/HRP20191785T1/hr unknown
- 2019-10-11 CY CY20191101074T patent/CY1122166T1/el unknown
-
2021
- 2021-01-28 US US17/160,814 patent/US20210148940A1/en not_active Abandoned
-
2023
- 2023-08-09 US US18/231,880 patent/US20240280593A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12398176B2 (en) | 2018-08-27 | 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Use of Raman spectroscopy in downstream purification |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240280593A1 (en) | Method for separating target molecules or particles from fibrinogen-containing samples including blood components | |
| US20090269788A1 (en) | Method for detecting microorganism | |
| US20190276868A1 (en) | Methods for Detecting Microorganisms Using Microorganism Detection Protein and Other Applications of Cell Binding Components | |
| US10281466B2 (en) | Method of detecting an analyte using chromatographic enrichment | |
| US10634672B2 (en) | Method of detecting a microorganism using chromatographic enrichment | |
| KR102571662B1 (ko) | 샘플 수집 및 가공 장치 | |
| HK1247280B (zh) | 用於从含纤维蛋白原的样品中分离目标分子或颗粒的方法 | |
| JP2023523627A (ja) | メチシリン耐性黄色ブドウ球菌を検出するための組成物、方法およびシステム | |
| US20240336950A1 (en) | Use of a Sustainable, Modified and Enhanced Aquaculture Limulus Amebocyte Lysate Protein for Detection and Characterization of Infectious Pathogens in Biologic Samples for Patient Screening, Diagnosis and Therapeutic Management | |
| WO2012088412A2 (en) | Capture and enrichment of organisms and cells from liquids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160829 |